Table 1.
The contributions of CDC in the context of the potent tolerizing effects of DST plus anti-CD154 mAb treatment regimen in recipients of islet allografts
| Donor | Recipients | Treatment | Graft survival |
|---|---|---|---|
| DBA/2 | B6AF1 | untreated | 9, 11, 13, 15, 17 |
| DBA/2 | B6AF1 | DSTa + MR1b | >150 n=10 |
| DBA/2 | B6AF1 | DSTa + MR1b + CVFc | 15, 15, 19, 29, 32 |
| B6AF1 | DBA/2 | untreated | 13, 14, 15, 20 |
| B6AF1 | DBA/2 | DSTa | 13, 13, 14, 15, 15 |
| B6AF1 | DBA/2 | DSTa + MR1b | 20, 24, 24, 40, >120 |
| B6AF1 | Balb/c | untreated | 9, 11, 13, 15, 17 |
| B6AF1 | Balb/c | DSTa | 7, 7, 8, 9, 10, 12 |
| B6AF1 | Balb/c | DSTa + MR1b | >60, >60, >60, >60 |
| 129 CD40KO | Balb/c CD40KO | untreated | 9, 12, 13, 17 |
| 129 CD40KO | Balb/c CD40KO | DSTa | 6, 6, 7, 9, 10 |
| 129 CD40KO | Balb/c CD40KO | DSTa + MR1b | 8, 19, 22, >120, >120, >120 |
a
DST consisted of 0.25 mL fresh donor whole blood administered 28 days before transplantation.
b
MR1 anti-CD154 mAb was given at a single dose of 0.5 mg/mouse intravenously 28 days before transplantation.
c
CVF was given at a dose of 60 units/kg intraperitoneally 28 days before transplantation followed by 20 units/kg per day for 14 consecutive days.
DST, donor specific transfusion; CVF, cobra venom factor.